0 (0%)		09-27 09:33
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	11.27	1-year :	13.16
Resists	First :	9.64	Second :	11.27
Pivot price	9.48
Supports	First :	9.42	Second :	9.27
MAs	MA(5) :	9.49	MA(20) :	9.48
	MA(100) :	4.73	MA(250) :	3.73
MACD	MACD :	0.6	Signal :	0.8
%K %D	K(14,3) :	55.1	D(3) :	52.8
RSI	RSI(14): 75.3
52-week	High :	9.64	Low :	1.87

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PSTX ] has closed below upper band by 42.4%. Bollinger Bands are 90% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	9.51 - 9.55	9.55 - 9.59
Low:	9.38 - 9.43	9.43 - 9.48
Close:	9.41 - 9.5	9.5 - 9.57

Thu, 25 Sep 2025
Plus Therapeutics (PSTX) Surges After Securing UnitedHealthcare Coverage for CNSide Test - GuruFocus

Wed, 08 Jan 2025
Roche to close $1.5B acquisition of Poseida Therapeutics (OTCQX:RHHBY) - Seeking Alpha

Fri, 13 Dec 2024
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance

Mon, 09 Dec 2024
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PR Newswire

Wed, 27 Nov 2024
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX - The Malaysian Reserve

Tue, 26 Nov 2024
Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition - MedCity News

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	97 (M)
Shares Float	65 (M)
Held by Insiders	27.6 (%)
Held by Institutions	58.4 (%)
Shares Short	3,590 (K)
Shares Short P.Month	4,610 (K)

EPS	-0.63
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.88
Profit Margin	-40.3 %
Operating Margin	27.5 %
Return on Assets (ttm)	-13.2 %
Return on Equity (ttm)	-57.7 %
Qtrly Rev. Growth	667.2 %
Gross Profit (p.s.)	-0.23
Sales Per Share	1.54
EBITDA (p.s.)	-0.59
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-22 (M)

PE Ratio	-15.08
PEG Ratio	0
Price to Book value	10.67
Price to Sales	6.13
Price to Cash Flow	-61.65

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.